Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Jason J. Luke

Has grant

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Recent Grants

Grant: Open

Immune Exclusion in Cancer Immunotherapy

Open Date: 2022-09-01

Close Date: 2027-07-31

Grant: Open

PITT-CAL ETCTN PK Resource Laboratory

Open Date: 2020-05-15

Close Date: 2027-02-28

Grant: Close

Genomic and Commensal Variants Associated with Immunotherapy in Cancer Patients

Open Date: 2017-08-15

Close Date: 2021-08-14

Grant: Open

NCI ETCTN Pittsburgh Cancer Consortium (PCC)

Open Date: 2014-03-25

Close Date: 2027-02-28

Grant: Open

Cancer Center Support Grant

Open Date: 1988-08-01

Close Date: 2027-07-31

Articles (21)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (10)

Daniel J. Smit

Research Group Leader / Physician

University Medical Center Hamburg-Eppendorf

GERMANY

View details

Ann Silk

Dana-Farber Cancer Institute

UNITED STATES

View details

Amir Jazaeri

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Tobias Holderried

Professor of Cellular Immunotherapy

Medical University of Graz

AUSTRIA

View details

Simone M Goldinger

University of Queensland

AUSTRALIA

View details

Alexander Christopher Jonathan van Akkooi

Associate Professor

Melanoma Institute Australia

AUSTRALIA

View details

Christoph Hoeller

Associate Professor, Head of Skin Cancer Center

Medical University of Vienna

AUSTRIA

View details

John Haanen

Chair of Translational Immunotherapy of Cancer

Leiden University Medical Center

NETHERLANDS

View details

Daniel D Brown

Senior Research Scientist

University of Pittsburgh

UNITED STATES

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jason J. Luke

Research Interests

Explore related searches

Recent Grants

Articles (21)

Translating ctDNA into cutaneous melanoma care: An international expert survey

Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles

Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials

Phase I Dose Escalation and Cohort Expansion of Lorigerlimab, a Bispecific PD-1 × CTLA-4 DART Molecule With Focus on Metastatic Castration-Resistant Prostate Cancer

Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial

IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma

Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors

Priorities for local immunotherapy research and drug development

Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas

Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy

Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial

And… We’re Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer

Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma

Top advances of the year: Melanoma

Collaborators (10)

Daniel J. Smit

Ann Silk

Amir Jazaeri

Tobias Holderried

Simone M Goldinger

Alexander Christopher Jonathan van Akkooi

Christoph Hoeller

John Haanen

Daniel D Brown

Timothy Yap

Make your next move.